To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrineresponsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves diseasefree survival for postmenopausal women with endocrineresponsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high. © Springer Science+Business Media, LLC. 2008. [International Breast Cancer Study Group (IBCSG) ]
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 / O. Pagani, S.G.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 116:3(2009 Aug), pp. 491-500. [10.1007/s10549-008-0225-9]
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
M. ColleoniMembro del Collaboration Group
;A. VeronesiMembro del Collaboration Group
;M. CastiglioneMembro del Collaboration Group
;G. VialeMembro del Collaboration Group
;L. OrlandoMembro del Collaboration Group
;S. DellapasquaMembro del Collaboration Group
;G. CuriglianoMembro del Collaboration Group
;F. De BraudMembro del Collaboration Group
;R. OrecchiaMembro del Collaboration Group
;A. CostaMembro del Collaboration Group
;S. ZurridaMembro del Collaboration Group
;P. VeronesiMembro del Collaboration Group
;V. SacchiniMembro del Collaboration Group
;P. ReyMembro del Collaboration Group
;M. ForniMembro del Collaboration Group
;A. SchindlerMembro del Collaboration Group
;
2009
Abstract
To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrineresponsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves diseasefree survival for postmenopausal women with endocrineresponsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high. © Springer Science+Business Media, LLC. 2008. [International Breast Cancer Study Group (IBCSG) ]| File | Dimensione | Formato | |
|---|---|---|---|
|
s10549-008-0225-9.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
281.05 kB
Formato
Adobe PDF
|
281.05 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




